These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38935348)

  • 1. A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.
    Silva-Pilipich N; Smerdou C
    Clin Cancer Res; 2024 Sep; 30(17):3649-3651. PubMed ID: 38935348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.
    Ji Q; Wu Y; Albers A; Fang M; Qian X
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
    Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
    Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.
    Hirvinen M; Heiskanen R; Oksanen M; Pesonen S; Liikanen I; Joensuu T; Kanerva A; Cerullo V; Hemminki A
    J Transl Med; 2013 Aug; 11():193. PubMed ID: 23965133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
    Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Milenova I; Verhoeff J; Heiniö C; Zafar S; Garcia-Vallejo JJ; van Beusechem VW; de Gruijl TD; Kalervo A; Sorsa S; Kanerva A; Hemminki A
    Front Immunol; 2021; 12():706517. PubMed ID: 34367166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
    Pakola SA; Peltola KJ; Clubb JHA; Jirovec E; Haybout L; Kudling TV; Alanko T; Korpisaari R; Juteau S; Jaakkola M; Sormunen J; Kemppainen J; Hemmes A; Pellinen T; van der Heijden M; Quixabeira DCA; Kistler C; Sorsa S; Havunen R; Santos JM; Cervera-Carrascon V; Hemminki A
    Clin Cancer Res; 2024 Sep; 30(17):3715-3725. PubMed ID: 38546220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
    Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
    Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
    Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.
    Chalikonda S; Kivlen MH; O'Malley ME; Eric Dong XD; McCart JA; Gorry MC; Yin XY; Brown CK; Zeh HJ; Guo ZS; Bartlett DL
    Cancer Gene Ther; 2008 Feb; 15(2):115-25. PubMed ID: 18084242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
    Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
    Front Immunol; 2022; 13():794251. PubMed ID: 35355980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.
    Hemminki O; Oksanen M; Taipale K; Liikanen I; Koski A; Joensuu T; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2018 Jun; 9():41-50. PubMed ID: 29989063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus.
    He X; Yao W; Zhu JD; Jin X; Liu XY; Zhang KJ; Zhao SL
    J Transl Med; 2023 Oct; 21(1):688. PubMed ID: 37789452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma.
    Kim W; Seong J; Oh HJ; Koom WS; Choi KJ; Yun CO
    J Radiat Res; 2011; 52(5):646-54. PubMed ID: 21952320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.